A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. (Q34627272)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. |
scientific article |
Statements
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis (English)
A Novotna
S Ratcliffe
I Novakova
M Vachova
O Zapletalova
C Pozzilli
L Cefaro
G Comi
P Rossi
Z Ambler
Z Stelmasiak
A Erdmann
A Klimek
P Davies
Sativex Spasticity Study Group